Publication Date
11-15-2026
Abstract
For over sixty years, the Food & Drug Administration (FDA) has had the authority to review the safety and efficacy of new prescription drugs before they enter the United States market. Given recent legal and political events, this Article explores a no-longer hypothetical question: what would happen to the regulation of prescription drugs and other healthcare technologies in a world without FDA? Who—if anyone—could determine whether or not healthcare technologies are safe and effective? This Article examines not only critical actions that FDA takes to ensure the safety and efficacy of new healthcare technologies, but also the reasons why FDA exists in the first place and the theories motivating those actions. Analyzing the FDA’s functions and its animating goals allows for the identification of other institutional actors and legal tools whose work overlaps with FDA’s, however partially. This Article concludes that at present, no other institutional actor has the resources and institutional capabilities to fully replace FDA, and a post-FDA world would be harmful to patient safety, to innovation, and to the development of information about the safety and efficacy of new healthcare technologies. In a limited set of cases, however, there may be potential for different actors—most likely, other countries’ pharmaceutical regulators, but potentially insurance companies or independent nonprofit entities—to limit the damage posed by ongoing events. Going forward, rebuilding or replacement will be necessary to provide the adequate infrastructure to perform the FDA’s functions.
Recommended Citation
Rachel E. Sachs,
Regulating Healthcare Technologies in a Post-FDA World,
121
Nw. U. L. Rev.
631
(2026).
https://scholarlycommons.law.northwestern.edu/nulr/vol121/iss3/2
Included in
Administrative Law Commons, Food and Drug Law Commons, Health Law and Policy Commons, Law and Society Commons, President/Executive Department Commons